CORRESP Filing
Ensysce Biosciences, Inc.
Date: April 22, 2025 · CIK: 0001716947 · Accession: 0001641172-25-005656
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286580
Letter
Ensysce Biosciences, Inc.
Ivanhoe Avenue, Suite 201
La Jolla, California 92037
April 22, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, NE
Washington, D.C. 20549
Attention: Tyler Howes, Esq.
Re: Ensysce Biosciences, Inc.
Registration Statement on Form S-3
SEC File No. 333-286580
Filed April 16, 2025
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc. (the " Company ") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-286580) (the " Registration Statement ") be accelerated to 4:00 PM, Eastern Time, on April 24, 2025, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Locke LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Locke LLP, by calling Eric D. Kline at (412) 454-5046 or Gregory Rubis at (609) 951-4105.
Please direct any questions or comments concerning this request to Eric Kline or Gregory Rubis.
ENSYSCE BIOSCIENCES, Inc.
By: /s/ Lynn Kirkpatrick
Name: Dr. Lynn Kirkpatrick
Title: President and Chief Executive Officer
cc: Eric D. Kline, Troutman Pepper Locke LLP
Gregory Rubis, Troutman Pepper Locke LLP
Show Raw Text
CORRESP 1 filename1.htm Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Tyler Howes, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 SEC File No. 333-286580 Filed April 16, 2025 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc. (the " Company ") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-286580) (the " Registration Statement ") be accelerated to 4:00 PM, Eastern Time, on April 24, 2025, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Locke LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Locke LLP, by calling Eric D. Kline at (412) 454-5046 or Gregory Rubis at (609) 951-4105. Please direct any questions or comments concerning this request to Eric Kline or Gregory Rubis. ENSYSCE BIOSCIENCES, Inc. By: /s/ Lynn Kirkpatrick Name: Dr. Lynn Kirkpatrick Title: President and Chief Executive Officer cc: Eric D. Kline, Troutman Pepper Locke LLP Gregory Rubis, Troutman Pepper Locke LLP